Literature DB >> 11772426

Gut-acting drugs for lowering cholesterol.

Donald M Black1.   

Abstract

Drugs that indirectly lower blood cholesterol through their actions in the gut have been used for many years. Their utility has been limited by poor tolerability, and hence, poor compliance. New resins are better tolerated and offer an advantage to older drugs. New strategies focusing on reducing serum cholesterol by acting on the gastrointestinal tract may hold even greater promise, combining the safety of nonsystemic agents with the acceptance of statins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11772426     DOI: 10.1007/s11883-002-0065-8

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  5 in total

1.  Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism.

Authors:  S M Grundy; E H Ahrens; G Salen
Journal:  J Lab Clin Med       Date:  1971-07

2.  Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.

Authors:  M H Davidson; M A Dillon; B Gordon; P Jones; J Samuels; S Weiss; J Isaacsohn; P Toth; S K Burke
Journal:  Arch Intern Med       Date:  1999-09-13

3.  Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively.

Authors:  D Hunninghake; W Insull; P Toth; D Davidson; J M Donovan; S K Burke
Journal:  Atherosclerosis       Date:  2001-10       Impact factor: 5.162

4.  Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.

Authors:  H H Knapp; H Schrott; P Ma; R Knopp; B Chin; J M Gaziano; J M Donovan; S K Burke; M H Davidson
Journal:  Am J Med       Date:  2001-04-01       Impact factor: 4.965

5.  Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias.

Authors:  H Buchwald; R L Varco; J R Boen; S E Williams; B J Hansen; C T Campos; G S Campbell; M B Pearce; A E Yellin; W A Edmiston; R D Smink; H S Sawin
Journal:  Arch Intern Med       Date:  1998-06-08
  5 in total
  2 in total

Review 1.  Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council.

Authors:  Robert A Hegele; Samuel S Gidding; Henry N Ginsberg; Ruth McPherson; Frederick J Raal; Daniel J Rader; Jennifer G Robinson; Francine K Welty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-09-16       Impact factor: 8.311

Review 2.  Cholesterol metabolism and therapeutic targets: rationale for targeting multiple metabolic pathways.

Authors:  Stephen D Turley
Journal:  Clin Cardiol       Date:  2004-06       Impact factor: 2.882

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.